




Our Innovation Network



About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com

Contact Information
Investor Relations
CH-4070 Basel
Switzerland
Email: investor_relations@roche.com
Website: www.roche.com/investors

Additional Information

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Information accessed herein may not under any circumstances be used for the purpose of, or in connection with, the quotation of any securities on an automated inter-dealer quotation system within the meaning of Rule 12g3-2(b) under the Securities Exchange Act of 1934.

A Leader in Personalised Healthcare

Pharmaceuticals	Diagnostics	Industry Leadership
#1 R&D Investment as % of 2021 revenue vs top Pharma peers	#1 Core Lab company based on 2022 revenue	#1 In neurology and <i>in vitro</i> diagnostics market
16 Blockbuster drugs based on 2022 global sales	29 Billion test results produced with Roche systems in 2022	14 Years running Roche ranked as one of the top 3 most sustainable healthcare companies in the Dow Jones Sustainability Indices
14 Million patients treated with Roche medicines	809 Million COVID tests conducted in 2022 with Roche products	103,613 Employees
32 Roche medicines on the WHO list of essential medicines	3 FDA Breakthrough Device Designations Granted for Roche diagnostics in 2022	150+ Countries
267 Thousand patients participated in clinical trials		

Overview of our financials

2022 Roche Group

63.3 CHF Bn

in Sales
(Pharmaceuticals and
Diagnostics)

22.6 CHF Bn

in Core Operating Profit

14.1 CHF Bn

in R&D Core
Investment


36 years

of consecutive
Dividend increases*


Overall net sales figures

Sales by business areas for Pharmaceuticals and Diagnostics for the past three years

CHF total billions




Diversification of Roche business




Research & Development

CHF total billions (% of sales)




Core Operating Profit

CHF total billions (% of sales)




Core Earnings per Share

CHF



Operating Free Cash Flow


CHF total billions



Sharing our success with investors

2022 Dividend as approved by the board of directors at the annual general meeting

Gross dividend for Roche – ROG.SW



Note: For 1995 a special dividend was paid out to mark F. Hoffmann-La Roche's 100th anniversary in 1996

5-Year dividend history


Year	Dividend per share ROG.SW CHF
2022	9.50
2021	9.30
2020	9.10
2019	9.00
2018	8.70

Our Pharmaceutical successes

All 10 of the Roche Group's top 10 selling pharmaceuticals are blockbusters that have sales of more than 1B CHF per year. The Roche Group also currently has one of the strongest pharmaceutical development pipelines in the industry, with biotechnology products accounting for a significant part of all projects. For more information, visit: <https://www.roche.com/solutions/pipeline/>

Roche Pharmaceutical – Top 5 products in 2022

CHF total billions



Roche Pharmaceuticals – Pipeline in 2022

